Drug Profile


Alternative Names: AFP 168; DE-085; DE-118; MK-2452; Saflutan; Taflotan; Tapros; Tapros mini ophthalmic solution 0.0015%; Tapros ophthalmic solution 0.0015%; Zioptan

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santen Pharmaceutical
  • Developer Merck & Co; Santen Pharmaceutical
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 03 Jul 2017 Santen Oy completes a phase I trial in Glaucoma and Ocular hypertension (In children, In adolescent) in USA, Hungary, Slovakia, Poland and United Kingdom (NCT02102750)
  • 01 Apr 2016 Preservative-free formulation launched for Glaucoma and Ocular hypertension in Singapore (Santen pipeline, July 2016)
  • 01 Mar 2016 Launched for Ocular hypertension and Glaucoma in China (Ophthalmic) (Santen pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top